-
China’s Multi-Bureau Plan Aims to Eradicate Cervical Cancer by 2030
•
The National Health Commission (NHC), Ministry of Education, Ministry of Civil Affairs, and six other bureaus have released the “Accelerating the Eradication of Cervical Cancer Action Plan.” The initiative seeks to establish a multi-bureau network focused on driving cervical cancer prevention and control mechanisms with the goal of eradicating the…
-
JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911
•
Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by its US subsidiary VITRAC Therapeutics, LLC for its small molecule aurora A kinase (AURKA) inhibitor VIC-1911. The molecule is being assessed both as a monotherapy and in combination with sotorasib for the treatment of KRAS…
-
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
•
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as part of an upfront fee paid by US-based Summit Therapeutics Inc. (NASDAQ: SMMT) under the firms’ December 2022 licensing deal for the bispecific antibody (BsAb) ivonescimab. The initial payment includes USD 274.9 million in cash…
-
NMPA Proposes Emergency Use Management Measures for Medical Devices
•
The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures” for public consultation. The draft proposals are open for feedback until February 15, 2023. These measures aim to streamline the emergency use of medical devices, particularly during public health emergencies. Emergency Use CriteriaEmergency use will…
-
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
•
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune diseases, has announced the latest data for its pan-fibroblast growth factor receptor (FGFR) inhibitor gunagratinib (ICP-192) in cholangiocarcinoma at the ASCO-GI 2023 meeting. The findings highlight the drug’s potential in treating this challenging form of…
-
Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD
•
Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US FDA to conduct a Phase I clinical study for its EXG102-031. The study will assess the safety, tolerability, and vision improvement potential of this once-administered gene therapy in patients with wet age-related macular degeneration (wAMD).…
-
Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for its Cosela (trilaciclib) at the Jilin Cancer Hospital. This milestone marks the official clinical application of the first-in-class CDK4/6 inhibitor in China. Drug Background and DevelopmentTrilaciclib, discovered by US biotech G1 Therapeutics Inc., was in-licensed…
-
China Updates Export Controls on Technologies, Adds Gene Editing to List
•
The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted from export from China. The update includes the removal of 32 items, revision of 36 items, and the addition of 7 new items. The list now comprises 24 technologies prohibited from export and 115 with…
